Jan 30, 2025
Immutep Quarterly Activities Report Q2 FY25
Jan 21, 2025
Patient Enrolment Completed for EFTISARC-NEO Phase II Trial
Jan 06, 2025
Patient Enrolment Completed for INSIGHT-003
Dec 16, 2024
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761
Dec 15, 2024
Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II
Dec 11, 2024
Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024
Dec 09, 2024
Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
Nov 14, 2024
Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting
Oct 28, 2024
Immutep Quarterly Activities Report Q1 FY25
Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024
Oct 17, 2024
Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial
